Leading brokers name 3 ASX shares to buy today

Here's why brokers rate these ASX shares as buys…

| More on:
ASX shares Business man marking buy on board and underlining it

Image Source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

With so many shares to choose from on the ASX, it can be hard to decide which ones to buy. The good news is that brokers across the country are doing a lot of the hard work for you.

Three top ASX shares leading brokers have named as buys this week are listed below. Here's why they are bullish on them:

Allkem Ltd (ASX: AKE)

According to a note out of Bell Potter, its analysts have a buy rating and $17.53 price target on this lithium miner's shares. Its analysts are positive on lithium prices and expect supply constraints to keep them higher for the foreseeable future. Bell Potter expects this to underpin significant improvements in cash generation and profits in the coming years. The broker also likes Allkem due to its aim of maintaining a 10% share of supply in a global lithium market experiencing unprecedented growth. The Allkem share price was trading at $9.80 on Monday.

Brambles Limited (ASX: BXB)

A note out of Ord Minnett reveals that its analysts have retained their buy rating and $13.50 price target on this logistics solutions company's shares. Its analysts believe that the current Brambles share price implies an overly punitive earnings multiple of just 2x EBITDA on the company's struggling Americas business. This compares to an estimated 12x EBITDA for its other businesses. So, with its Americas operations now starting to show early signs of a recovery, it could be a good time to invest. The Brambles share price is fetching $10.51 today.

Paradigm Biopharmaceuticals Ltd (ASX: PAR)

Another note out of Bell Potter reveals that its analysts have retained their buy rating but trimmed their price target on this biopharmaceutical company's shares to $1.90. Bell Potter has reduced its valuation to reflect the ongoing correction to biotechnology sector valuations. However, it remains positive and believes upcoming data from the OA-008 osteoarthritis study could represent a significant catalyst. The Paradigm share price was trading at 98 cents on Monday.

Motley Fool contributor James Mickleboro has positions in Allkem Limited. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Broker Notes

Stethoscope with a piggy bank in the middle.
Broker Notes

Australian health insurance: Does Macquarie prefer Medibank or NIB shares?

Medibank and NIB shares have both surged in 2025. Here’s what Macquarie expects now.

Read more »

Man smiling at a laptop because of a rising share price.
Broker Notes

9 ASX 200 shares just upgraded to strong buy ratings

Brokers have upgraded these shares amid expectations of price growth over the next 12 months.

Read more »

Red sell button on an Apple keyboard.
Broker Notes

Sell alert! Brokers say pull the plug on these 3 ASX 200 shares

Experts say it's time to press the sell button on these ASX 200 shares. Find out why.

Read more »

Overjoyed man celebrating success with yes gesture after getting some good news on mobile.
Broker Notes

Macquarie forecasts 40% upside for this ASX All Ords stock

Let's see which stock the broker is tipping as a buy.

Read more »

Contented looking man leans back in his chair at his desk and smiles.
Broker Notes

Leading brokers name 3 ASX shares to buy today

Here's why brokers believe that now could be the time to snap up these shares.

Read more »

A smiling woman with a handful of $100 notes, indicating strong dividend payments
Broker Notes

Where to invest $10,000 in ASX 200 shares this month

Brokers think these shares could be top picks for your hard-earned money this month.

Read more »

A young woman lifts her red glasses with one hand as she takes a closer look at news about interest rates rising and one expert's surprising recommendation as to which ASX shares to buy
Broker Notes

Top brokers name 3 ASX shares to buy next week

Brokers gave buy ratings to these ASX shares last week. Why are they bullish?

Read more »

Man with rocket wings which have flames coming out of them.
Broker Notes

These ASX 200 shares could rise 40%+

Big returns could be on offer from these shares according to analysts.

Read more »